AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10716460
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (0 or 5,000 IU)
Trial: 9184580
Drug: Adenosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (2 mg/min)
Trial: 8263864
Drug: Postoperative fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative fluid instillation (1-2 L)
Trial: 2993733
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (35 g)
Trial: 29508539
Drug: Therapist-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-delivered cognitive behavioural therapy
Trial: 29508539
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioural therapy
Trial: 27170728
Drug: OJ with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OJ with 5.5 g added orange pomace fiber (OPF)
Trial: 24950270
Drug: Perineal low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineal low rectal dissection
Trial: 24950270
Drug: Abdominal low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal low rectal dissection
Trial: 19829124
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (1200 mg intravenously during the procedure and 1200 mg orally two times daily for the next 48 h after percutaneous coronary intervention)
Trial: 16137113
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg docosahexaenoic acid (DHA)
Trial: 16137113
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg 5‐methyl‐tetra‐hydro‐folate (5‐MTHF)
Trial: 16137113
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 500 mg DHA and 400 mg 5‐MTHF
Trial: 11875284
Drug: Stimulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant treatment
Trial: 373852
Drug: Salbutamol given
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol given intravenously (500 microgram injection)
Trial: 373852
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (IPPB and intravenous)
Trial: 30112581
Drug: Neural mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural mobilization (NM) exercises targeting the median, musculocutaneous, femoral, and saphenous nerve, performed twice daily for 4-8 weeks.
Trial: 27506836
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy in women aged 65-79 years
Trial: 25888828
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention (test groups)
Trial: 25888828
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention (test 1 group)
Trial: 25888828
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention (test 2 group)
Trial: 24004621
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SRP and occlusal adjustment
Trial: 19178509
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion at a rate of 2 pmol/kg/min for 4 h
Trial: 19178509
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 4 h
Trial: 19178509
Drug: GLP‐1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP‐1 infusion at a rate of 1 pmol/kg/min for 4 h
Trial: 19178509
Drug: Ad libitum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad libitum energy intake after all four infusions
Trial: 17102935
Drug: Intervention not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention not specified, but involves three treatments for borderline personality disorder (BPD).
Trial: 11032702
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 6.0 mg/kg
Trial: 11032702
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 12.0 mg/kg
Trial: 11032702
Drug: NN703 (tabimorelin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NN703 (tabimorelin) 1.5 mg/kg
Trial: 8339398
Drug: Scopolamine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (low doses, transdermal patch)
Trial: 3555041
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg orally every 12 hours)
Trial: 3555041
Drug: Cefotaxime (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2.0 g intravenously every 8 hours)
Trial: 25569408
Drug: Rectal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal ketamine (0.5 mg/kg)
Trial: 25569408
Drug: Local peritonsillar
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local peritonsillar ketamine (2 mg/kg)
Trial: 25569408
Drug: IV tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tramadol hydrochloride (2 mg/kg)
Trial: 22321929
Drug: Acute hypervolemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hypervolemic hemodilution (AHH) with 6% hydroxyethyl starch solution at 24 ml×kg(‐1)×h(‐1)
Trial: 22321929
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving compound electrolyte solution at 6 ml×kg(‐1)×h(‐1)
Trial: 18339727
Drug: Occupational Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Therapy (OT) - six home treatment sessions over 2 months
Trial: 11977294
Drug: Glucose-insulin-kalium (GIK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-kalium (GIK) mixture
Trial: 11977294
Drug: Placebo (physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (physiological saline infusion)
Trial: 9042978
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily after initial 1-week triple therapy
Trial: 9042978
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after initial 1-week triple therapy
Trial: 9042978
Drug: 1-week low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-week low-dose triple therapy (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d.)
Trial: 9042978
Drug: 1-week low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-week low-dose triple therapy
Trial: 2829958
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of fish oil daily containing approximately 1.8 g eicosapentaenoic acid
Trial: 21470751
Drug: Preoperative amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative amoxicillin
Trial: 21470751
Drug: Postoperative amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative amoxicillin
Trial: 16671837
Drug: Instructional music
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Instructional music therapy
Trial: 16671837
Drug: Both music
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both music therapy treatment groups
Trial: 12577332
Drug: Combined transdermal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined transdermal acupoint electric stimulation (TAES) and isoflurane anesthesia
Trial: 9225334
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice and protein-rich supplements
Trial: 27008542
Drug: D. pteronyssinus
RxNorm normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D. pteronyssinus subcutaneous allergen immunotherapy (DP-AIT) for 24 months
Trial: 27008542
Drug: D. pteronyssinus
RxNorm normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D. pteronyssinus subcutaneous allergen immunotherapy (DP-AIT)
Trial: 20470379
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/day orally for 2 years
Trial: 9856522
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (5 injections of 20 microg each)
Trial: 9856522
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination
Trial: 7751414
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion (CSI) of octreotide
Trial: 7751414
Drug: Intermittent subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent subcutaneous injection (ISI) of octreotide
Trial: 2236455
Drug: Mirtazapine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (18 mg)
Trial: 2236455
Drug: Amitriptyline (111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (111 mg)
Trial: 280956
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthwash (10 ml at 0.1%)
Trial: 12375796
Drug: Irinotecan in
RxNorm normalized name: irinotecan Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan in combination with radiation therapy
Trial: 31537189
Drug: Intravenous glibenclamide
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glibenclamide
Trial: 26376822
Drug: Punch biopsies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Punch biopsies with recall for treatment if CIN2/3 confirmed
Trial: 24989152
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy informed psychotherapy (CBT-ip) only
Trial: 24989152
Drug: CBT-ip with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT-ip with medication (sertraline)
Trial: 24989152
Drug: Medication (sertraline)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (sertraline) only
Trial: 18029489
Drug: Almonds (84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds (84 g daily for 4 weeks)
Trial: 18029489
Drug: Pork (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork (120 g daily for 4 weeks)
Trial: 16148184
Drug: Antibodies in
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies in lymphocyte supernatant (ALS) assay
Trial: 16148184
Drug: Antibody‐secreting cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody‐secreting cell (ASC) assay
Trial: 8777097
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of insulin (1.25 u. h‐1) (Group B)
Trial: 8777097
Drug: Insulin 10
RxNorm normalized name: Human regular insulin 100 unit/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin 10 u. i.v. boluses every 2 h (Group C)
Trial: 29427697
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to medication adherence
Trial: 16265344
Drug: Raltitrexed-oxaliplatin (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed-oxaliplatin (arm A): raltitrexed 3 mg m(‐2) followed by oxaliplatin 130 mg m(‐2) on day 1, repeated every 3 weeks
Trial: 16265344
Drug: Raltitrexed-irinotecan (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed-irinotecan (arm B): CPT‐11 350 mg m(‐2) followed by raltitrexed 3 mg m(‐2), repeated every 3 weeks
Trial: 10200809
Drug: Twice-weekly, six-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly, six-month progressive walking programme
Trial: 2357134
Drug: Long peritoneal
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long peritoneal lavage (LPL) for 7 days compared to other treatments
Trial: 2357134
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments (without lavage or lavage for 2 to 4 days)
Trial: 395629
Drug: Cimetidine, 400
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 400 mg at night
Trial: 31282006
Drug: liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide (3.0 mg)
Trial: 24372992
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg day(‐1)
Trial: 24372992
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg day(‐1)
Trial: 24372992
Drug: Aspirin 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 3.6 g day(‐1)
Trial: 19605528
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (SPI) (80 mg/d aglycone isoflavones)
Trial: 17478338
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein plus vitamins, minerals, and antioxidants
Trial: 15669556
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) vaginal cream (0.625 mg/g) applied once daily on days 1-21 of two 28-day cycles
Trial: 7599569
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) 4 g/m2 alone
Trial: 7599569
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CY) 4 g/m2 followed by GM‐CSF 250 micrograms/m2 or G‐CSF 600 micrograms
Trial: 7599569
Drug: Post-transplant ANC
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant ANC > = 500 x 10(6)/l
Trial: 7599569
Drug: Post-transplant platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplant platelet count > = 50 x 10(6)/l
Trial: 28101704
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CON) - 17.2 kJ gross energy/g diet
Trial: 28101704
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein group (HP) - 19.4 kJ gross energy/g diet
Trial: 28101704
Drug: High fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fat group (HF) - 19.9 kJ gross energy/g diet
Trial: 28101704
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate group (HC) - 19.1 kJ gross energy/g diet
Trial: 27647058
Drug: No nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No nicotine patches (usual care)
Trial: 17312332
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (12 weekly injections, targeting hemoglobin levels between 120 and 140 g/L)
Trial: 15142880
Drug: Timed-sequential induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed-sequential induction (arm C)
Trial: 9021439
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg tirilazad mesylate every 6 hours for 29 doses (6.0 mg/kg/day for 7 days)
Trial: 9021439
Drug: 3.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg tirilazad mesylate every 6 hours for 29 doses (12.0 mg/kg/day for 7 days)
Trial: 9021439
Drug: 4.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg/kg tirilazad mesylate every 6 hours for 29 doses (16.0 mg/kg/day for 7 days)
Trial: 1875538
Drug: ONO 3708
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO 3708 (2.5 micrograms.kg‐1.min‐1 given with continuous infusion)
Trial: 1087137
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate once per month with citrovorum rescue for 3 months
Trial: 1087137
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of methotrexate and immunization monthly for 3 months
Trial: 1087137
Drug: Combination immunochemotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immunochemotherapy
Trial: 27979834
Drug: Ciclosporin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin 2.5 mg/kg as an intravenous injection after anaesthesia induction but before start of surgery
Trial: 27979834
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as an intravenous injection after anaesthesia induction but before start of surgery
Trial: 27979834
Drug: Ciclosporin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin 2.5 mg/kg
Trial: 21331635
Drug: Ozone treatment
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone treatment (60 s)
Trial: 21331635
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ozone treatment)
Trial: 19602718
Drug: TETA 100
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA 100 mg
Trial: 19602718
Drug: TETA 300
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA 300 mg
Trial: 19602718
Drug: TETA 600
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA 600 mg
Trial: 19602718
Drug: TETA 1800
RxNorm normalized name: TETA
DrugBank: Triethylenetetramine (DB06824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TETA 1800 mg
Trial: 15280678
Drug: Conventional cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cyclosporine triple therapy
Trial: 96461
Drug: Ciclazindol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclazindol (100 mg/day)
Trial: 31397184
Drug: TIO/FORMfixed (18/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO/FORMfixed (18/12 µg once daily via Discair inhaler)
Trial: 31397184
Drug: TIO/FORMbid (tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIO/FORMbid (tiotropium 18 µg by Handihaler + formoterol 12 µg twice daily by Aerolizer)
Trial: 31397184
Drug: TIOmono (tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIOmono (tiotropium 18 µg by Handihaler)
Trial: 17532101
Drug: PsA‐TT vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PsA‐TT vaccine (Group 1)
Trial: 17532101
Drug: Meningococcal Polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal Polysaccharide Vaccine A+C (Group 2)
Trial: 17532101
Drug: Tetanus Toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus Toxoid Vaccine Adsorbed (Group 3)
Trial: 14985695
Drug: Once-a-week 2800
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-a-week 2800 microg folic acid supplement
Trial: 14985695
Drug: Daily 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 400 microg folic acid supplement
Trial: 7893272
Drug: Other silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other silymarin preparations
Trial: 30693096
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatment alongside usual IAPT care